Patents by Inventor Arnon Rosenthal

Arnon Rosenthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190010230
    Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
    Type: Application
    Filed: September 21, 2018
    Publication date: January 10, 2019
    Applicant: Alector LLC
    Inventors: Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, Ilaria TASSI, Helen LAM, Arnon ROSENTHAL
  • ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190002560
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 11, 2016
    Publication date: January 3, 2019
    Applicant: ALECTOR LLC
    Inventors: Kate MONROE, Helen LAM, Francesca AVOGADRI-CONNORS, Seung-Joo LEE, William MONTEITH, Herve RHINN, Arnon ROSENTHAL
  • Anti-sortilin antibodies and methods of use thereof
    Patent number: 10087255
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 2, 2018
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180265586
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: January 10, 2018
    Publication date: September 20, 2018
    Applicant: ALECTOR LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
  • ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180244770
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 26, 2016
    Publication date: August 30, 2018
    Applicant: Alector LLC
    Inventors: Kate MONROE, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Francesca AVOGADRI-CONNORS, William MONTEITH
  • CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
    Publication number: 20180186855
    Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent a neurological disease, disorder, or injury.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 5, 2018
    Applicant: ALECTOR LLC
    Inventor: Arnon ROSENTHAL
  • CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
    Publication number: 20180186878
    Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.
    Type: Application
    Filed: April 26, 2017
    Publication date: July 5, 2018
    Applicant: ALECTOR LLC
    Inventor: Arnon ROSENTHAL
  • SIGLEC TRANSGENIC MICE AND METHODS OF USE THEREOF
    Publication number: 20180160661
    Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 14, 2018
    Applicant: ALECTOR LLC
    Inventors: Arnon ROSENTHAL, Seung-Joo LEE
  • METHODS FOR TREATING HEADACHE USING ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE
    Publication number: 20180162931
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 14, 2018
    Inventors: Joerg Zeller, Kristian Todd Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 9890210
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 13, 2018
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 9890211
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 13, 2018
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 9884908
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 6, 2018
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 9884907
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 6, 2018
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTI-NGF ANTIBODIES AND METHODS USING SAME
    Publication number: 20170342143
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Application
    Filed: June 14, 2017
    Publication date: November 30, 2017
    Inventors: Jaume PONS, Arnon ROSENTHAL
  • ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
    Publication number: 20170334976
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Application
    Filed: April 19, 2017
    Publication date: November 23, 2017
    Inventors: Arnon Rosenthal, Michael Leviten
  • Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide
    Publication number: 20170240624
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide
    Publication number: 20170240625
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170240631
    Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
    Type: Application
    Filed: August 8, 2015
    Publication date: August 24, 2017
    Applicant: ALECTOR LLC
    Inventors: Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, IIaria TASSI, Helen LAM, Arnon ROSENTHAL
  • Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide
    Publication number: 20170240623
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide
    Publication number: 20170240622
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal